Recent Advances in Pharmacotherapy of Ulcerative Colitis

DOI:

https://doi.org/10.37285/ijpsn.2014.7.1.2

Authors

  • Ajay Kumar Pareek
  • S K Garg
  • Saini P
  • P Pitliya
  • S L Choudhary
  • D Puri
  • S Bhambu

Abstract

Ulcerative colitis is a form of chronic inflammatory bowel disease (IBD) that produces inflammation and ulcers along the inside of the colon, which can interfere with the normal function of the colon. The disease typically starts to manifest in patients as young adults.  Ulcerative colitis is an intermittent disease with periods of exacerbated symptoms, or flares, and periods that are relatively symptom-free. According to the Cohn’s and Colitis Foundation of America, several millions people suffer from ulcerative colitis worldwide. Current therapeutic approaches for ulcerative colitis are partially successful despites advances in GIT research. A significant proportion of patients with ulcerative colitis undergo colectomy. Nearly 50% patients do not achieve sustained remission, leading to impairment of physical and mental health, social life, employment issues and sexual activity. Budesonide is an oral, extended release synthetic corticosteroid that is recently approved for UC.  Enteric-coated budesonide formulations resist gastric-acid degradation, delivering active drug to the small intestine and proximal colon. Budesonide is specifically indicated for the induction of remission in patients with active, mild to moderate ulcerative colitis. Budesonide has a high first-pass metabolism with minimal systemic absorption. This review describes recent advances in the pharmacotherapy of ulcerative colitis and outlines why future studies targeting sustained suppression of inflammation could have an enormous impact on the natural course of the disease. Ulcerative colitis needs intense therapy and it should be maintained until sustained remission and mucosal healing has been reached.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Keywords:

Ulcerative colitis, budesonide, remission, inflammation, IBD, corticosteroids

Downloads

Published

2014-02-28

How to Cite

1.
Pareek AK, Garg SK, P S, Pitliya P, Choudhary SL, Puri D, et al. Recent Advances in Pharmacotherapy of Ulcerative Colitis. Scopus Indexed [Internet]. 2014 Feb. 28 [cited 2024 Jun. 16];7(1):2230-7. Available from: https://www.ijpsnonline.com/index.php/ijpsn/article/view/695

Issue

Section

Review Articles

References

Baumgart DC and Sandborn WJ (2007). Inflammatory bowel disease: clinical aspects and established and evolving therapies. The Lancet 369(9573): 1641-57.

Bibiloni R, Fedorak RN and Tannock GW (2005). VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis. Am J Gastroenterol 100(7): 1539-46.

Borody TJ, Warren EF, Leis SM, Surace R, Ashman O and Siarakas S (2004). Bacteriotherapy using fecal flora: toying with human motions. J Clin Gastroenterol 38(6): 475–83.

Borody TJ, Warren EF, Leis S, Surace R and Ashman O (2003). Treatment of ulcerative colitis using fecal bacteriotherapy. J Clin Gastroenterol. 37(1): 42–47.

Burger D and Travis S (2011). Conventional medical management of inflammatory bowel disease. Gastroenterology. 140(6): 1827-1837.e2.

Calkins BM (1989). A meta-analysis of the role of smoking in inflammatory bowel disease. Dig Dis Sci 34(12): 1841–54.

Card T, Hubbard R and Logan RF (2003). Mortality in inflammatory bowel disease: a population-based cohort study. Gastroenterology 125(6): 1583–1590.

Cohen AD, Dreiher J and Birkenfeld S (2009). Psoriasis associated with ulcerative colitis and Crohn's disease. J Eur Acad Dermatol Venereol. 23(5): 561–565.

Corrao G, Tragnone A and Caprilli R (1998). Risk of inflammatory bowel disease attributable to smoking, oral contraception and breastfeeding in Italy: a nationwide case-control study. Cooperative Investigators of the Italian Group for the Study of the Colon and the Rectum (GISC). Int J Epidemiol. 27(3): 397–404.

Cotran RS, Collins T, Robbins SL and Kumar V (1998). Pathologic Basis of Disease. Philadelphia, Pa: WB Saunders; 11-19.

Danese S and Fiocci C (2011). Ulcerative colitis. N Engl J Med. 365: 1713-1725.

Devlin S and Panaccione R (2010). Evolving Inflammatory Bowel Disease Treatment Paradigms: Top-Down versus Step-Up. Medical Clinics of North America. 94(1):1-18.

Dichi I, Frenhane P, Dichi JB, et al., (2000). Comparison of omega-3 fatty acids and sulfasalazine in ulcerative colitis. Nutrition 16: 87-90.

Falt A, Bengtsson T, Kennedy B, et al., (2007). Exposure of infants to budesonide through breast milk of asthmatic mothers. J. Allergys Clin Immunol 120(4): 798-802.

Farmer RG, Easley KA and Rankin GB (1993). Clinical patterns, natural history, and progression of ulcerative colitis. A long-term follow-up of 1116 patients. Dig. Dis. Sci. 38(6): 1137–1146.

Fauci et al (2008). Harrison's Internal Medicine, 17th Ed. New York: McGraw-Hill Medical.

Garland CF, Lilienfeld AM, Mendeloff AI, Markowitz JA, Terrell KB and Garland FC (1981). Incidence rates of ulcerative colitis and Crohn's disease in fifteen areas of the United States. Gastroenterology. 81(6): 1115-24

Gionchetti P, Rizzello F, Venturi A and Campieri M (2000). Probiotics in infective diarrhea and inflammatory bowel diseases. J Gastroenterol Hepatol 15(5):489-493.

Guslandi M (1999). Nicotine treatment for ulcerative colitis. Br J Clin Pharmacol 48(4): 481–4.

Haas L, McClain C and Varilek G (2000). Complementary and alternative medicine and gastrointestinal diseases. Curr Opin Gastroenterol 16(2): 188-196.

Hanauer SB and Hanauer SB (1996). Inflammatory bowel disease. N Engl J Med. 334(13): 841–8.

Jang ES, Lee DH, Kim J, Yang HJ, Lee SH and Park YS (2009). Age as a clinical predictor of relapse after induction therapy in ulcerative colitis. Hepatogastroenterology. 56(94-95): 1304-9.

Joos S, Wildau N and Kohnen R (2006). Acupuncture and moxibustion in the treatment of ulcerative colitis: a randomized controlled study. Scand J Gastroenterol. 41(9): 1056-1063

Kim IK, Park KJ and Kang GH (2012). Risk factors for complications after total colectomy in ulcerative colitis. The Turkish journal of Gastroenterology. 23(5): 22-27.

Kornbluth A and Sachar DB (2004). Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 99(7): 1371–1385.

Kozuch PL and Hanauer SB (2008). Treatment of inflammatory bowel disease: A review of medical therapy. World J Gastroenterol. 14(3): 354-77.

Lakatos PL, Szamosi T and Lakatos L (2007). Smoking in inflammatory bowel diseases: good, bad or ugly. World J Gastroenterol. 13(46): 6134–9.

Ling SC and Griffiths AM (2000). Nutrition in inflammatory bowel disease. Curr Opin Clin Metab Car. 3(5): 339-344.

Orholm M, Binder V, Sørensen TI, Rasmussen LP and Kyvik KO (2000). Concordance of inflammatory bowel disease among Danish twins. Results of a nationwide study. Scand J Gastroenterol. 35(10): 1075–81.

Rachmilewitz D (1989). Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ. 298(6666): 82–86.

Rutgeerts P, Vermeire S and Van Assche G (2009). Biological therapies for inflammatory bowel diseases. Gastroenterology. 136(4):1182-1197.

Sands BE and Siegel CA (2010). Crohn's disease. In: Feldman M, Friedman LS, Brandt, LJ, eds. Sleisenger & Fordtran's Gastrointestinal and Liver Disease. 9th ed. Philadelphia, Pa: Saunders Elsevier.

Sandborn WJ, Travis S, Moro L, Jones R, Gautille T, Bagin R, Huang M, Yeung P and Ballard ED (2012). Once-daily budesonide MMX® extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I study. Gastroenterology. 143(5): 1218-26

Sharma HN and Sharma KK (2007). Principles of pharmacology, first edition. Paras Medical Publisher 415-417.

Silverman MS, Davis I and Pillai DR (2010). Success of self-administered home fecal transplantation for chronic Clostridium difficile infection. Clin Gastroenterol Hepatol. 8(5): 471–473.

Solberg IC, Lygren I and Jahnsen J (2008). Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study). Scand J Gastroenterol. 44(4): 431–440.

Stremmel W, Merle U, Zahn A, Autschbach F, Hinz U and Ehehalt R (2005). Retarded release phosphatidylcholine benefits patients with chronic active ulcerative colitis. Gut. 54(7): 966–971

Truelove SC and Witts LJ (1955). Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J. 2(4947): 1041–1048.

Tysk C, Lindberg E, Jarnerot G and Floderus-Myrhed B (1988). Ulcerative colitis and Crohn's disease in an unselected population of monozygotic and dizygotic twins. A study of heritability and the influence of smoking. Gut. 29(7): 990–996

Most read articles by the same author(s)